Post-Marketing Observational Prospective Study to Assess Real World Outcomes and the Risk of Myelodysplastic syndromes (MDS)/acute myeloid leukaemia (AML) in Platinum Sensitive Relapsed breast cancer susceptibility gene (BRCA) Mutated Ovarian Cancer Patients Treated with Lynparza (olaparib); the LOCALISE Study

30/06/2016
02/07/2024
EU PAS number:
EUPAS13757
Study
Finalised
Documents
Study protocol
Study results
Study report
Other information